Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Sanofi SA Add to portfolio

STX:SAN, Apr 21, 07:01 UTC

Latest STX:SAN News

Filter your feed

Apply Filter

Yesterday


News

Polish regulator OKs Santander unit rebranding

SAN

"WARSAW (Reuters) - Polish regulator KNF said on Friday it had accepted Bank Zachodni WBK's (BZW.WA) plan to rebrand to Santander Bank Polska, despite previous criticism of the move.", "In 2014, Santander (SAN.MC) unit BZ WBK's Chief Executive Mateusz Morawiecki, now Poland's Prime Minister, was forced to abandon rebranding after criticism from KNF. Since then, KNF management has been replaced.", '"The rebranding case was accepted by KNF taking into account Santander\'s investor obligations and in line with the law," a KNF spokesman said in an emailed comment to Reuters on Friday, without giving further details.', 'Next week, BZ WBK presents its first quarter results and is expected to address questions regarding the plan. Some analysts estimate the cost of rebranding at around 50 million zloty (10.70 million pounds). What to read next.'

Read Full Details

Topics:
  • Business
  • Politics
  • Financial
News

Why the Santander share price could smash the FTSE 100 this year

SAN

Shares in Santander(LSE: BNC), Europe’s largest bank by market capitalisation, often get overlooked because they are not exciting enough. However, while the bank’s slow and steady approach to business may not be exciting, it does mean that the group has been able to avoid many of the problems its European peers have suffered and is now one of the world’s dominant players. The group was able to avoid the worst of the financial crisis, thanks to its exposure to emerging markets, specifically Brazil which today accounts for one-quarter of overall earnings. Unfortunately, as Europe has recovered over the past five years, Brazil has struggled, and so has the firm’s US division. But it now looks as if these problems are behind the group, and for the first time in around a decade, Santander seems as if it has entered 2018 firing on all cylinders. Considering all of the above, I believe 2018 is set to be a blowout year for the Santander share price.

Read Full Details

Topics:
  • Business
  • Financial
  • Entertainment

Thursday, April 19


News

BRIEF-Sanofi confident in Dengvaxia's safety and potential

SAN

BRIEF-Sanofi confident in Dengvaxia's safety and potential. (Reuters) - Sanofi SA:. * SANOFI SAYS CONFIDENT IN DENGVAXIA’S SAFETY AND PROVEN POTENTIAL TO REDUCE DENGUE DISEASE BURDEN IN ENDEMIC COUNTRIES. * SANOFI SAYS DENGUE CONTINUES TO REPRESENT A SIGNIFICANT PUBLIC HEALTH CHALLENGE. * SANOFI SAYS TO CONTINUE LONG-TERM COMMITMENT TO GLOBAL DENGUE BURDEN REDUCTION. * SANOFI SAYS TO CONTINUE WORK WITH INTERNATIONAL PUBLIC HEALTH COMMUNITY AND ENDEMIC COUNTRIES Further company coverage: (Paris Newsroom). Next Article. Walmart could buy controlling stake in Flipkart as early as next week - sources.

Read Full Details

Topics:
  • Business
  • Technology
  • Science
  • Financial
News

Sanofi to Divest European Generic Unit, Streamline Business

SAN

Sanofi to Divest European Generic Unit, Streamline Business. ZacksApril 19, 2018. Sanofi SNY has entered into exclusive negotiations with private equity firm, Advent International to sell its European generic unit, Zentiva. Advent has offered a binding and fully financed offer to buy Zentiva for $2.4 billion (1.9 billion euros). The potential divesture of Zentiva is part of Sanofi’s 2020 strategic roadmap to streamline its business. Sanofi remains committed to its Generics business in other parts of the world and will focus on developing the same in the emerging markets. The transaction is expected to close by the end of this year, subject to finalizing of definitive agreements and approval from relevant regulatory authorities. Shares of Sanofi have lost 5.4% so far this year compared with the industry’s 2.7% decrease. Sanofi is shifting its focus toward businesses with higher potential for growth like rare disease drugs and biotechnology. In 2018 so far, the company has spent almost $16 billion in acquiring assets in these segments, which include Bioverativ Inc. for hemophilia treatments and Ablynx NV for a rare bleeding disorder candidate. Sanofi swapped its animal health business with Boehringer Ingelheim’s consumer healthcare (“CHC”) business in early 2017, building a strong and innovative CHC Global Business Unit. Per an article posted on Bloomberg.com, generics is an expanding market in Europe with several patent expirations of branded drugs in the cards. However, competition and pricing pressure are also increasing along with governments’ effort to cut healthcare cost. Sanofi’s decision to sell Zentiva is prudent in this tough market. Investors expect Sanofi to invest the proceeds from this sale in acquiring other biotechs. However, Sanofi is not the only company re-prioritizing and consolidating its products and pipeline. Novartis AG NVS acquired US-based AveXis Inc. to add a rare disease candidate to its pipeline. GlaxoSmithKline GSK has announced that it will transfer its rare disease gene therapy portfolio to private biotech, Orchard Therapeutics. Both the deals happened last week. Earlier this week, Shire SHPG announced the sale of its Oncology business to France-based company, Servier, to focus on rare disease leadership. Sanofi Price. Sanofi Price | Sanofi Quote. Sanofi carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. The Hottest Tech Mega-Trend of All. Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >>. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report GlaxoSmithKline plc (GSK) : Free Stock Analysis Report Shire plc (SHPG) : Free Stock Analysis Report To read this article on Zacks.com click here. What to read next.

Read Full Details

Story Sources

finance.yahoo.com
Topics:
  • Business
  • Health
  • Financial
News

Santander bank worker admits embezzlement

SAN

'A bank worker has admitted helping to embezzle more than £50,000 from customers.', 'Rameez Ahmed Hamid, 32, took details including security information from clients of Santander bank, where he worked.', 'At Glasgow Sheriff Court Hamid, from Coatbridge in North Lanarkshire, pled guilty to embezzling £51,706 between June 2014 and February 2015, while acting with other unknown people.', 'Procurator fiscal depute Richard Hill said: "On January 3, 2015 Santander received a phone call whereby a new account in the name of Mr Ward was opened and a new bank card and personal identification number was sent to the new address. "On January 12, 2015, two transfers from Mr Ward\'s accounts to the new account were processed to the value of £22,133 and £25,073.'

Read Full Details

Story Sources

bbc.com bbc.co.uk
Topics:
  • Business
  • Financial
  • Science

Wednesday, April 18


News

Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker

SAN

'April 17, 2018, 1:53 PM EDT Updated on April 18, 2018, 3:39 AM EDT.', 'Sanofi Chief Financial Officer Jerome Contamine is planning to step down from the French drugmaker later this year after almost a decade in the job.', 'Contamine has informed the company of his intent to retire, and will help with finding a replacement and assist with the transition once a successor has been named, a spokesman for the Paris-based drugmaker said by telephone.', 'He is a graduate of both the Ecole Polytechnique and the Ecole Nationale d’Administration, two of France’s top schools, and started his corporate career at Elf Aquitaine SA, the French oil company from which Sanofi was created.'

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, April 17


News

Sanofi's CFO Contamine to retire later this year

SAN

Sanofi's CFO Contamine to retire later this year. PARIS (Reuters) - Sanofi's <SASY.PA> executive vice president and chief financial officer, Jerome Contamine, plans to retire later this year, the French drugmaker said on Tuesday. In an emailed statement, a spokesman with Sanofi said Contamine would "work with the company on finding a replacement and assist with the transition once a successor has been named". Contamine, 60, a graduate of Ecole Polytechnique, France's most prestigious engineering school, joined Sanofi in 2009 after holding a senior management position with water and waste group Veolia <VIE.PA>. What to read next.

Read Full Details

Topics:
  • Business
  • Financial
News

Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker

SAN

Sanofi Chief Financial Officer Jerome Contamine is planning to step down from the French drugmaker later this year after almost a decade in the job.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Santander has several hurdles to clear in race on Britain’s high streets

SAN

Santander has several hurdles to clear in race on Britain’s high streets | Business. When a Spanish bank bought Abbey National in 2004, there was mild shock that a British institution was falling to a foreign lender. No one expected it to be the start of a deal spree that made Santander one of the biggest banks on the high street with a brand made familiar by advertising featuring Dame Jessica Ennis-Hill, Jenson Button and others. It even attracted a political heavyweight as its UK chairwoman: Baroness Vadera, a former minister, joined in 2015. Yet observers say that Santander’s cheery public profile masks private, behind-the-scene tension. A programme to improve controls and training is seen by some as a sign that Santander is under pressure to raise its game and by others as a cause for uncertainty among its….

Read Full Details

Topics:
  • Business
  • Financial
News

Santander fund invests in Brazil fintech - BNamericas

SAN

This information is available only to subscribers. Start a free trial, to unlock the full potential of a subscription to BNamericas. This news article is one of hundreds published daily by Business News Americas about the commodities, markets, movements, companies, projects, economics and politics integral to the development of Latin America. The business development service focuses on major projects, active companies, such as and business and sales contacts, providing networking opportunities with leading executives throughout Latin America.

Read Full Details

Topics:
  • Business
  • Financial
  • Science